The quantal theory of immunity

Cell Research

Volumn 16, Issue 1, 2006, Pages 11-19

  Smith, Kendall A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Immune system; Interleukin 2 (IL2); Macromolecular complex; Quantal (all or none); Self:nonself recognition; T cell antigen receptor (TCR)

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

CELL CYCLE; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; THYMUS;

AUTOANTIGENS; CELL CYCLE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; INTERLEUKIN-2; INTRACELLULAR SPACE; RECEPTORS, INTERLEUKIN-2; SELF TOLERANCE; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; THYMUS GLAND;

EID: 31144467483     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310003     Document Type: Review

References (69)

1. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 1957; 20:67.
2. Jerne NK. The natural selection theory of antibody formation. Proc Natl Acad Sci U S A 1955; 41:849.
3. Quantal. http://www.m-w.com/dictionary/quantal
4. Schrodinger E. Cat experiment. 1935; http://www.mtnmath.com/faq/meas-qm- 3.html
5. Smith KA. The quantal theory of how the immune system discriminates between "self and non-self". Med Immunol 2004; 3:3.
6. Smith KA, Favata MF, Oroszlan S. Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J Immunol 1983; 131:1808.
7. Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981; 154:1455.
8. Baker PE, Gillis S, Smith KA. Monoclonal cytolytic T-cell lines. J Exp Med 1979; 149:273.
9. Leonard WJ, Depper JM, Uchiyama T, et al. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 1982; 300:267.
10. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120:2027.
11. Kane A. Dose-response. http://aquaticpath.umd.edu/appliedtox/dose- response.pdf
12. Parks DR, Bryan VM, Oi VT, Herzenberg LA. Antigen-Specific Identification and Cloning of Hybridomas with a Fluorescence-Activated Cell Sorter. Proc Nat Acad Sci U S A 1979; 76:1962.
13. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984; 224:1312.
14. Pardee A, Shilo B, Koch A. Variability of the cell cycle. In: Hormones and Cell Culture. Sato G, Ross R, eds. Cold Spring Harbor Laboratory, Cold Spring Harbor: NY 1979; 373.
15. Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166:1055.
16. Smith KA. The interleukin 2 receptor. Annu Rev Cell Biol 1989; 5:397.
17. Rickert M, Boulanger M, Goriatcheva N, Garcia K. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin 2 and its alpha, beta and gamma receptors. J Mol Biol 2004; 339:1115.
18. Smith KA, Cantrell DA. Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A 1985; 82:864.
19. Leonard W, Shores E, Love P. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol Rev 1995; 148:97.
20. Liparoto SF, Myszka DG, Wu Z, et al. Analysis of the role of the interleukin-2 receptor chain in ligand binding. Biochemistry 2002; 41:2543.
21. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159.
22. Stauber D, Debler E, Horton P, Smith K, Wilson I. Crystal structure of the interleukin-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2005 In press.
23. Ihle JN. Cytokine receptor signalling. Nature 1995; 377:591.
24. Martino A, Holmes JH 4th, Lord JD, Moon JJ, Nelson BH. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 2001; 166:1723.
25. Moon JJ, Nelson BH. Phosphatidylinositol 3-kinase potentiates, but does not trigger, T cell proliferation mediated by the IL-2 receptor. J Immunol 2001; 167:2714.
26. Moon J, Rubio E, Martino A, Krumm A, Nelson B. Apermissive role for phophatidylinositol 3-kinase in the STAT5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem 2004; 279:5520.
27. Stern JB, Smith KA. Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science 1986; 233:203.
28. Beadling C, Johnson KW, Smith KA. Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci U S A 1993; 90:2719.
29. Beadling C, Smith KA. DNA array analysis of interleukin-2-regulated immediate/early genes. Med Immunol 2002; 1:2
30. Pardee A. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 1974; 71:1286.
31. Sherr C. D-type cyclins. Trends in Biochem Sci 1995; 20:187.
32. Sherr C, Roberts J. CDK inhibitors: positive and negative regulators of G1 progression. Genes & Development 1999; 13:1501.
33. Sherr C. The pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689.
34. Holbrook NJ, Smith KA, Fornace AJ Jr, et al. T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci U S A 1984; 81:1634.
35. Garrity PA, Chen D, Rothenberg EV, Wold BJ. Interleukin 2 transcription is regulated in vivo at the level of coordinated binding of both constitutive and regulated factors. Molecular and Cellular Biology 1994; 14:2159.
36. Rothenberg EV, Ward SB. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc Natl Academ Sci U S A 1996; 93:9358.
37. Shaw JP, Utz PJ, Durand DB, et al. Identification of a putative regulator of early T cell activation genes. Science 1988; 241:202.
38. Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T cell activation. Nature 1994; 369:497.
39. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991; 251:313.
40. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell- derived lymphokines/cytokines. Proc Natl Acad Sci U S A 1989; 86:1333.
41. Verweij CL, Geerts M, Aarden LA. Activation of interleukin 2 gene transcription via the T cell surface molecule CD28 is mediated through anNF-kB-like response element. J Biol Chem 1991; 266:14179.
42. Ghosh P, Tan TH, Rice NR, Sica A, Young HA. The interleukin 2 CD28-responsive complex contains at least three members of the NF-kB family: c-Rel, p50, and p65. Proceedings of the National Academy of Sciences USA 1993; 90:1696.
43. Liou H, Jin Z, Tumang J, et al. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999; 11:361.
44. Jenkins M, Schwartz R. Antgen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165:302.
45. Macian F, Garcia-Rodriguez C, Rao A. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. Embo J 2000; 19:4783.
46. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001; 20:2476.
47. Macian F, Garcia-Cozar F, Im SH, et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109:719.
48. Macian F, Im SH, Garcia-Cozar FJ, Rao A. T-cell anergy. Curr Opin Immunol 2004; 16:209.
49. Heissmeyer V, Macian F, Im SH, et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004; 5:255.
50. Chiodetti L, Barber D, Schwartz R. Biallelic expression of the IL-2 locus under optimal stimulation conditions. Eur J Immunol 2000; 30:2157.
51. Itoh Y, Germain RN. Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells. J Exp Med 1997; 186:757.
52. Hemmer B, Stefanova I, Vergelli M, Germain RN, Martin R. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998; 160:5807.
53. Gett A, Sallusto F, Lanzavecchia A, Geginat J. T cell fitness determined by signal strength. Nat Immunol 2003; 4:355.
54. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273:104.
55. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998; 8:89.
56. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996; 183:1917.
57. Monks C, Freiberg B, Kupfer H, Sciaky N, Kupfer A. Three dimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395:82.
58. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285:221.
59. Huppa J, Gleimer M, Sumen C, Davis M. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 2003; 4:749.
60. Huppa J, Davis M. T-cell antigen recognition and the immunological synapse. Nat Rev Immunol 2003; 3:973.
61. Hesse MD, Karulin AY, Boehm BO, Lehmann PV, Tary-Lehmann M. A T cell clone's avidity is a function of its activation state. J Immunol 2001; 167:1353.
62. Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need? Immunity 2001; 15:71.
63. Krummel M, Davis M. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol 2002; 14:66.
64. Li Q, Dinner A, Qi S, et al. CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol 2004; 5:791.
65. Krogsgaard M, Li QJ, Sumen C, et al. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 2005; 434:238.
66. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287.
67. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. 2001; 2:301.
68. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172:6519.
69. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp-3-expressing regulatory T cells. Nat Immunol 2005; 6:1142.